Answers are grounded in this paper and cite their sources.
In two independent retrospective studies, Mikhael et al and Venner et al report unprecedentedly high hematologic response rates, 94% and 81%, including complete response (CR) in 71% and 42%, respectively, to the combination of cyclophosphamide-bortezomib-dexamethasone in patients with either naive
No takes yet. Share an insight, caveat, or question.
Giampaolo Merlini (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: